CA2295199C - Method for treating vascular proliferative diseases with p27 and fusions thereof - Google Patents

Method for treating vascular proliferative diseases with p27 and fusions thereof Download PDF

Info

Publication number
CA2295199C
CA2295199C CA002295199A CA2295199A CA2295199C CA 2295199 C CA2295199 C CA 2295199C CA 002295199 A CA002295199 A CA 002295199A CA 2295199 A CA2295199 A CA 2295199A CA 2295199 C CA2295199 C CA 2295199C
Authority
CA
Canada
Prior art keywords
gene
cells
native
polypeptide
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002295199A
Other languages
English (en)
French (fr)
Other versions
CA2295199A1 (en
Inventor
Gary J. Nabel
Elizabeth G. Nabel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of CA2295199A1 publication Critical patent/CA2295199A1/en
Application granted granted Critical
Publication of CA2295199C publication Critical patent/CA2295199C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA002295199A 1997-07-21 1998-07-21 Method for treating vascular proliferative diseases with p27 and fusions thereof Expired - Fee Related CA2295199C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/897,333 US6177272B1 (en) 1997-07-21 1997-07-21 Method for treating vascular proliferative diseases with p27 and fusions thereof
US08/897,333 1997-07-21
PCT/US1998/015025 WO1999003508A2 (en) 1997-07-21 1998-07-21 METHOD FOR TREATING VASCULAR PROLIFERATIVE DISEASES WITH p27 AND FUSIONS THEREOF

Publications (2)

Publication Number Publication Date
CA2295199A1 CA2295199A1 (en) 1999-01-28
CA2295199C true CA2295199C (en) 2007-07-03

Family

ID=25407780

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002295199A Expired - Fee Related CA2295199C (en) 1997-07-21 1998-07-21 Method for treating vascular proliferative diseases with p27 and fusions thereof

Country Status (8)

Country Link
US (2) US6177272B1 (OSRAM)
EP (1) EP0998307B1 (OSRAM)
JP (1) JP2001510028A (OSRAM)
AT (1) ATE342067T1 (OSRAM)
AU (1) AU8502198A (OSRAM)
CA (1) CA2295199C (OSRAM)
DE (1) DE69836139T2 (OSRAM)
WO (1) WO1999003508A2 (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
US6413943B1 (en) 1999-03-01 2002-07-02 Cell Genesys, Inc. Methods and reagents for inhibiting proliferation of smooth muscle cells
IL145067A0 (en) * 1999-03-01 2002-06-30 Cell Genesys Inc Nucleic acid composition containing a first sequence encoding a chimeric cyclin-dependent kinase protein and a second sequence encoding an adenovirus e4 protein
US6420345B1 (en) * 1999-03-01 2002-07-16 Cell Genesys, Inc. Methods and reagents for inhibiting angiogenesis
JP4684512B2 (ja) * 1999-09-22 2011-05-18 信之 宮坂 ｐ２１Ｃｉｐ１リウマチ治療剤
US20040243097A1 (en) * 2000-05-12 2004-12-02 Robert Falotico Antiproliferative drug and delivery device
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) * 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
AU9486901A (en) * 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
US20020051730A1 (en) * 2000-09-29 2002-05-02 Stanko Bodnar Coated medical devices and sterilization thereof
US7261735B2 (en) * 2001-05-07 2007-08-28 Cordis Corporation Local drug delivery devices and methods for maintaining the drug coatings thereon
US20020111590A1 (en) * 2000-09-29 2002-08-15 Davila Luis A. Medical devices, drug coatings and methods for maintaining the drug coatings thereon
US20030013638A1 (en) * 2001-01-22 2003-01-16 Marks Andrew R. P27 prevents cellular migration
US20020098998A1 (en) * 2001-01-22 2002-07-25 Marks Andrew R. P27 prevents cellular migration
US7195640B2 (en) * 2001-09-25 2007-03-27 Cordis Corporation Coated medical devices for the treatment of vulnerable plaque
US20030065377A1 (en) * 2001-09-28 2003-04-03 Davila Luis A. Coated medical devices
US20030065345A1 (en) * 2001-09-28 2003-04-03 Kevin Weadock Anastomosis devices and methods for treating anastomotic sites
US7108701B2 (en) * 2001-09-28 2006-09-19 Ethicon, Inc. Drug releasing anastomosis devices and methods for treating anastomotic sites
WO2006031210A1 (en) 2003-05-29 2006-03-23 Board Of Regents, The University Of Texas Systems Jabi as a prognostic marker and a therapeutic target for human cancer
US7833339B2 (en) 2006-04-18 2010-11-16 Franklin Industrial Minerals Mineral filler composition
US8221738B2 (en) * 2008-02-19 2012-07-17 Celladon Corporation Method for enhanced uptake of viral vectors in the myocardium
KR20220051164A (ko) 2019-07-05 2022-04-26 아이오엠엑스 테라퓨틱스 아게 Igsf11 (vsig3)의 항체 결합 igc2 및 이의 용도
WO2022008027A1 (en) 2020-07-06 2022-01-13 Iomx Therapeutics Ag Antibodies binding igv of igsf11 (vsig3) and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US6355774B1 (en) 1994-01-07 2002-03-12 Fred Hutchinson Cancer Research Center Isolated p27 protein
US5688665A (en) 1994-01-07 1997-11-18 Fred Hutchinson Cancer Research Center Isolated nucleic acid molecules encoding the p27 KIP-1 protein
US6316208B1 (en) 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
US6242575B1 (en) 1994-01-07 2001-06-05 Fred Hutchinson Institute For Cancer Research Antibodies for detecting p27 protein
AU2770695A (en) 1994-07-15 1996-02-16 Fred Hutchinson Cancer Research Center Isolated p27 protein and methods for its production and use
AU5297496A (en) * 1995-02-17 1996-09-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods of preparation and use of recombinant adenoviral vectors
US5962424A (en) * 1995-02-21 1999-10-05 Arch Development Corporation Methods and compositions for targeting selectins
US5863904A (en) * 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US6541197B2 (en) * 1996-01-22 2003-04-01 Human Gene Therapy Research Institute Vehicles for stable transfer of green fluorescent protein gene and methods of use for same
US5672508A (en) * 1996-01-23 1997-09-30 Mitotix, Inc. Inhibitors of cell-cycle progression, and uses related thereto
WO1998021350A1 (en) * 1996-11-13 1998-05-22 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement

Also Published As

Publication number Publication date
CA2295199A1 (en) 1999-01-28
AU8502198A (en) 1999-02-10
WO1999003508A3 (en) 1999-04-08
EP0998307B1 (en) 2006-10-11
WO1999003508A9 (en) 1999-05-14
DE69836139D1 (de) 2006-11-23
US6177272B1 (en) 2001-01-23
JP2001510028A (ja) 2001-07-31
DE69836139T2 (de) 2007-08-16
WO1999003508A2 (en) 1999-01-28
US6884431B1 (en) 2005-04-26
EP0998307A2 (en) 2000-05-10
ATE342067T1 (de) 2006-11-15

Similar Documents

Publication Publication Date Title
US6177272B1 (en) Method for treating vascular proliferative diseases with p27 and fusions thereof
US5863904A (en) Methods for treating cancers and restenosis with P21
AP1011A (en) Defective recombinant virus and its use for treating hyperproliferative disorders, in particular restenosis.
JP4351896B2 (ja) ｐ３８／ＪＴＶ−１を有効成分とする癌治療用薬学的組成物及び癌治療用薬学的組成物のスクリーニング方法
US6737523B1 (en) Nucleic acids comprising regions of the rat PEG-3 promoter that display elevated expression in human cancer cells and uses thereof
JP2007532567A (ja) 神経障害および神経変性症状を治療するための方法と組成物
CN107099538B (zh) 抑制心肌肥厚的重组蛋白基因及其表达产物和应用
Fukuda et al. Cloning and characterization of a proliferation-associated cytokine-inducible protein, CIP29
JP2003508011A (ja) ヒトｆｅｚ１遺伝子である新規ガン抑制遺伝子に関する組成物、キットおよび方法
WO2003014340A2 (en) Human histone deacetylase-related gene and protein hdac10
CN112190709A (zh) 基质细胞蛋白ccn5组合物及其应用
US6670450B1 (en) Protein and gene involved in myocyte differentiation
CN105051061B (zh) 用于扩增干细胞的组合物和方法
KR20070011892A (ko) Ｍｓｘ1 단백질 또는 이를 코딩하는 유전자를유효성분으로 포함하는 세포사멸유도제
US6780986B1 (en) RIP60 nucleic acid and polypeptide sequences and uses therefor
US7202212B2 (en) Method for PR-39 peptide mediated selective inhibition of lκBα degradation
US20030166586A1 (en) C/EBP beta isoforms and methods of use in cell regulation and anti-tumorigenesis
US7087582B1 (en) Combination for site-specifically transforming cells in vivo comprising a double-balloon catheter and nucleic acid comprising a gene encoding P21
CA2416676A1 (en) Nucleic acids comprising regions of the rat peg-3 promoter and uses thereof
BG63548B1 (bg) Полипептиди, съдържащи протеинови домени на gax, включени в транскрипцията и/или взаимнодействащи сдруги протеини, съответни нуклеинови киселини и тяхното използване
US20070134229A1 (en) Non-native constitutively active osteopontin
JPH11506325A (ja) Δｐ６２、その変異体、核酸配列及びこれらの使用
HUP0104954A2 (hu) A PRV-1 gén és felhasználása
MXPA97007549A (en) Viral vectors and their use to treat disordershiperproliferativos, in particular resteno
JPH08337599A (ja) Ｉ κＢ αリン酸化抑制ペプチド

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed